Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study

Fig. 7

Observed percentage absenteeism of patients receiving UST or TNFi by achievement of effectiveness endpoints. a cDAPSA LDA/remission; b MDA; c VLDA; achievement of effectiveness endpoints represented by yes—target achieved, or no—target not achieved. Error bars represent 95% CIs. Absenteeism due to PsA is calculated for employed patients only, measured as work time missed (hours) in the last 7 days, expressed as a percentage. Abbreviations: cDAPSA, Clinical Disease Activity Index for Psoriatic Arthritis; CI, confidence interval; LDA, low disease activity; MDA, minimal disease activity; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor; UST, ustekinumab; VLDA, very low disease activity

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us